Furthermore, we have uncovered a novel role for MEK1/2 in the regulation of the tumor suppression functions of BCR that, in drug-resistant leukemia cells, has been demonstrated to be centered on the degradation of Myc [32, 34], a convergent key node protein for multiple resistance pathways [51–54]. This evidence concerns the gene MAP2K1 and leukemia.